Midcareer Investigator Award in Patient-Oriented Research (K24)

以患者为导向的研究中的职业中期研究者奖 (K24)

• 批准号: 8726286
• 负责人: Patricia L Hibberd
• 金额: $ 20.16万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8726286
• 关键词: Address; Adult; Antibodies; Applications Grants; Area; Attenuated; Award; Biological Markers; Biological Products; Biological Response Modifier Therapy; Boston; Childhood; Clinical; Clinical Investigator; Clinical Research; Collaborations; Communicable Diseases; Complement; Data; Data Set; Databases; Development; Doctor of Philosophy; Educational process of instructing; Elderly; Ethics; Faculty; Funding; Future; Gene Expression; Genes; Genetic Engineering; Goals; Grant; Health; Hour; Human; Immune response; Immunization; Immunoglobulin A; Immunologic Adjuvants; Individual Differences; Inflammatory; Influenza; Influenza vaccination; Knowledge; Lactobacillus; Life; Measures; Mentors; Messenger RNA; Microbe; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; National Center for Complementary and Alternative Medicine; Pediatric Hospitals; Pharmaceutical Preparations; Phase; Pilot Projects; Placebos; Population; Postdoctoral Fellow; Prevention; Probiotics; Property; Proteomics; Regulation; Research; Research Infrastructure; Research Methodology; Research Personnel; Resources; Role; ST14 gene; Safety; Science; Seasons; Signal Pathway; Solutions; Specimen; Spectrophotometry; Students; Technology; Testing; Therapeutic; Tissue Banking; Tissue Banks; Training; Training Support; Translational Research; United States National Institutes of Health; Vaccine Adjuvant; Vaccines; career; catalyst; clinical application; gastrointestinal; immunogenicity; improved; infectious disease treatment; inflammatory marker; influenza virus vaccine; innovation; interest; mRNA Expression; multidisciplinary; novel; novel strategies; open label; patient oriented; patient oriented research; peripheral blood; phase 1 study; prevent; programs; protein profiling; research study; respiratory; response; skills; urinary; vaccine efficacy; Address; Adult; Antibodies; Applications Grants; Area; Attenuated; Award; Biological Markers; Biological Products; Biological Response Modifier Therapy; Boston; Childhood; Clinical; Clinical Investigator; Clinical Research; Collaborations; Communicable Diseases; Complement; Data; Data Set; Databases; Development; Doctor of Philosophy; Educational process of instructing; Elderly; Ethics; Faculty; Funding; Future; Gene Expression; Genes; Genetic Engineering; Goals; Grant; Health; Hour; Human; Immune response; Immunization; Immunoglobulin A; Immunologic Adjuvants; Individual Differences; Inflammatory; Influenza; Influenza vaccination; Knowledge; Lactobacillus; Life; Measures; Mentors; Messenger RNA; Microbe; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; National Center for Complementary and Alternative Medicine; Pediatric Hospitals; Pharmaceutical Preparations; Phase; Pilot Projects; Placebos; Population; Postdoctoral Fellow; Prevention; Probiotics; Property; Proteomics; Regulation; Research; Research Infrastructure; Research Methodology; Research Personnel; Resources; Role; ST14 gene; Safety; Science; Seasons; Signal Pathway; Solutions; Specimen; Spectrophotometry; Students; Technology; Testing; Therapeutic; Tissue Banking; Tissue Banks; Training; Training Support; Translational Research; United States National Institutes of Health; Vaccine Adjuvant; Vaccines; career; catalyst; clinical application; gastrointestinal; immunogenicity; improved; infectious disease treatment; inflammatory marker; influenza virus vaccine; innovation; interest; mRNA Expression; multidisciplinary; novel; novel strategies; open label; patient oriented; patient oriented research; peripheral blood; phase 1 study; prevent; programs; protein profiling; research study; respiratory; response; skills; urinary; vaccine efficacy

DESCRIPTION (provided by applicant): Patricia Hibberd, MD, PhD is a clinical investigator dedicated to patient-oriented research. Of the 23 trainees partially or completely mentored during the first four years of her K24 award, 12 (52%) now have their own NIH grants, a vastly accelerated pace compared to her K24 award period. The overarching goal of her K24 Mid- Career Investigator Award in Patient-Oriented Research renewal grant is to advance probiotic science through high quality translational clinical research, novel collaborations to optimize the potential impact of probiotics on the prevention and treatment of infectious diseases, and innovative scientific solutions to the challenges of regulation of probiotics as bio-therapeutics. The renewal grant objectives are to continue to mentor students, post-doctoral fellows, and junior faculty who will conduct patient-oriented translational research to expand knowledge about host-microbe and microbe-microbe interactions, and to develop new avenues for clinical applications of probiotics. Her mentoring program will leverage the research and teaching infrastructure of the Harvard Catalyst/CTSA, as well as her two funded U01 grants and expertise of her multidisciplinary collaborators dedicated to the study of probiotics. Goals for the mentees are to obtain formal training in clinical/ translational research methodology, ethics, and regulatory science, to conduct mentored pilot studies and to develop grant applications for patient-oriented research. She will also provide longer-term career support through research "check-ups" to sustain the pool of well-trained clinical researchers as they embark on independent academic careers in meritorious CAM research. The new research direction in this renewal grant will greatly expand the goals of U01AT002952 to investigate the early response to influenza immunization (inactivated and live attenuated) in the elderly in subjects receiving probiotics as an immune adjuvant vs. placebo, by studying urinary protein profiles using mass spectrophotometry, with Harvard CTSA collaborators. Early vaccine responses 24, 48 and 72 hours after immunization, in the presence vs. absence of the probiotic immune adjuvant will be compared using proteomics. These data will greatly complement the U01 funded assessment of vaccine immune response that includes influenza titers (HAI and MN), systemic and mucosal IgA titers, and novel biomarkers such as the richness and diversity of gastrointestinal and respiratory microbiota and mRNA expression of pro and inflammatory genes and different signaling pathways 3, 4 and 8 weeks after influenza vaccine immunization. Proteomic profiles in vaccine responders vs. non-responders may improve understanding of individual differences in response of the elderly to immunization.

描述（由申请人提供）：帕特里夏·希伯德（Patricia Hibberd），医学博士，博士是致力于患者研究的临床研究者。在她的K24奖的前四年中，在23名学员中，有12名（52％）拥有自己的NIH赠款，与K24奖相比，这是一个大大加速的速度。她的K24中期职业研究员奖的总体目标是以患者为导向的研究更新授予授予授予授予授予的益生菌科学，通过高质量的转化临床研究，新颖的合作，以优化益生菌对预防和治疗传染性疾病的潜在影响，以及创新的科学解决方案，以及创新的科学解决方案，以对生物生物学的挑战，以实现生物生物学的挑战。更新的赠款目标是继续指导学生，博士后研究员和初级教师，他们将进行以患者为导向的转化研究，以扩大有关宿主 - 微生物和微生物微生物相互作用的知识，并为益生菌的临床应用开发新的途径。她的指导计划将利用哈佛大学催化剂/CTSA的研究和教学基础设施，以及她的两个资助的U01赠款和专业知识，专门用于益生菌研究。受训者的目标是获得临床/翻译研究方法，伦理学和监管科学的正式培训，以进行指导的试点研究并开发针对患者的研究的授予申请。她还将通过研究“检查”提供长期的职业支持，以维持训练有素的临床研究人员，因为他们从事有罪分子的独立学术职业。这项更新赠款的新研究方向将大大扩展U01AT002952的目标，以调查老年人在接受益生菌作为免疫辅助物质与安慰剂的受试者中对流感免疫接种的早期反应（失活和活跃的），并通过使用大规模分类仪表仪进行大规模分类辅助术，并协作研究，并通过大规模的尿液辅助。免疫后的早期疫苗反应24、48和72小时，在存在的情况下，将使用蛋白质组学比较益生菌免疫辅助剂。这些数据将大大补充包括流感滴度（HAI和MN），全身和粘膜IGA滴度在内的U01资助的评估，以及新型的生物标志物，例如胃肠道和呼吸道微生物群的丰富性和多样性，以及pro和炎症基因和炎症性基因的表达和炎症性基因和不同的IMSIGNAMED IMMIGNATION和不同的Immignation and Imberny Immun and Implactine 3周，4周，4周，4周。疫苗反应者与非反应者中的蛋白质组学特征可能会改善对老年人对免疫反应的个体差异的理解。